The Changing Coagulation Profile of Females: can Ultrastructure of Fibrin Teach Us Something?
Back to listIntroduction
Estrogen plays an important role during the life of a healthy female and impacts on the coagulation profile. Products that impact on the hemostatic health of women include contraception, as well as using hormone replacement later in life. Also, lifestyle habits like smoking are known to impact coagulation and hemostasis. Because hemostasis and estrogen are so closely linked to these lifestyle choices of women, it is suggested that an ultrastructure of fibrin networks may provide relevant insight into the changing coagulation profile of females.
Abstract
Estrogen plays an important role during the life of a healthy female and impacts on the coagulation profile. Products that impact on the hemostatic health of women include contraception, as well as using hormone replacement later in life. Also, lifestyle habits like smoking are known to have an impact on coagulation and hemostasis. Because hemostasis and estrogen are so closely linked to these lifestyle choices of women, it is suggested that an ultrastructure of fibrin networks may provide relevant insight into the changing coagulation profile of females. In the current research, the fibrin network in females, under different conditions, is studied using a scanning electron microscope. Control female profiles are compared with pregnancy, contraceptive use, hormone replacement, females who smoke, as well as females during old age. Here, we argue that the changes in the different stages of womanhood have a direct impact on the health and possibly thrombotic status in women. It is concluded that information provided by ultrastructural analysis during routine clinical history taking, might provide useful information regarding the most appropriate management or regime, particularly for women.
Keywords
SEM, ultrastructure, fibrin networks
Other Articles
- Effect of Adjusted and Non-Adjusted Citrate Concentrations on Coagulation Test Results in Patients With High Hematocrit Values—Breaking the Unproven Leap of Faith
- The Off-Label Use of Recombinant FVIIa in the Treatment of a Patient With T-Cell Non-Hodgkin Lymphoma Who Developed Intra-abdominal and Intra-Pleural Hemorrhages Followed by High-Dose Methotreaxate Therapy
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
